Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 8:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Low Metformin Clear all
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes

NCT03235050
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
MEDI0382 low dose, MEDI0382 mid dose, MEDI0382 high dose, Placebo, Liraglutide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
834 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
22
States / cities
Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2020 · Synced Sep 23, 2026, 8:57 PM EDT
Completed Phase 2 Interventional Results available

A Study in Type 2 Diabetics of Single and Multiple Doses of Orally Administered GSK1292263 to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics

NCT01119846
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
GSK1292263, GSK1292263 matching placebo, Sitagliptin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 60 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
7
States / cities
Phoenix, Arizona • Chula Vista, California • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2018 · Synced Sep 23, 2026, 8:57 PM EDT
Completed Not applicable Interventional Results available

Behavioral Economics and Self-Determination Theory to Change Diabetes Risk (BEST Change)

NCT04902326
View directory record Official record
Conditions
Pre Diabetes
Interventions
Automated educational text messages, Autonomy-supportive automated educational text messages, Financial incentives, Tailored text messages
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 28, 2024 · Synced Sep 23, 2026, 8:57 PM EDT
Suspended Phase 2 Interventional

Paxalisib With a High Fat, Low Carb Diet and Metformin for Glioblastoma

NCT05183204
View directory record Official record
Conditions
Glioblastoma
Interventions
Paxalisib, Metformin, Ketogenic Diet
Drug · Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Sep 23, 2026, 8:57 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Low Starch Dietary Education Program vs. Traditional Treatment for PCOS

NCT03916263
View directory record Official record
Conditions
PCOS, Diet Modification, Metabolism, Nutrition Disorders
Interventions
Metformin, One-On-One Dietary Instruction, Video Dietary Instruction
Drug · Other
Lead sponsor
Texas Tech University Health Sciences Center
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Aug 6, 2023 · Synced Sep 23, 2026, 8:57 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Dietary Intake of Tryptophan and Metformin Response

NCT02184832
View directory record Official record
Conditions
Metformin Response, Fasting Glucose, Tryptophan Concentration, Metformin Concentration, Diet Tolerability
Interventions
Metformin, Low tryptophan diet, High tryptophan diet
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
20 Years to 40 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 15, 2016 · Synced Sep 23, 2026, 8:57 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Lifestyle Intervention and Metformin for Women With Polycystic Ovary Syndrome (PCOS)

NCT00151411
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
Metformin, Placebo, Lifestyle Intervention
Drug · Behavioral
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
12 Years to 39 Years · Female only
Enrollment
114 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 20, 2018 · Synced Sep 23, 2026, 8:57 PM EDT
Completed Phase 2 Interventional

Safety and Feasibility of Metformin for Sepsis Induced AKI

NCT05900284
View directory record Official record
Conditions
Sepsis, Septic Shock, Acute Kidney Injury, Metformin
Interventions
Metformin low dose, Metformin high dose, Placebo
Drug
Lead sponsor
Hernando Gomez
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Sep 23, 2026, 8:57 PM EDT
Completed Early Phase 1 Interventional

Vitamin D Supplementation on 15-Prostaglandin Dehydrogenase Expression in Barrett's Esophagus

NCT01465113
View directory record Official record
Conditions
Short Segment Barrett's Esophagus, Long Segment Barrett's Esophagus
Interventions
Omeprazole, Vitamin D3, upper endoscopy, Metformin
Drug · Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
3
States / cities
Beachwood, Ohio • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 9, 2016 · Synced Sep 23, 2026, 8:57 PM EDT
Terminated Phase 2 Interventional Results available

Effects of Metformin on Low Back Pain

NCT04055012
View directory record Official record
Conditions
Low Back Pain
Interventions
Metformin, Placebo
Drug
Lead sponsor
Gwendolyn Sowa
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania • Wexford, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 20, 2025 · Synced Sep 23, 2026, 8:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Metformin Compared With Single Tablets

NCT01975220
View directory record Official record
Conditions
Healthy
Interventions
Empagliflozin/Metformin XR FDC, 25 mg Empagliflozin/1000 mg Metformin XR, FDC, 1 tablet Empagliflozin/2 tablets Metformin XR, 1 tablet Empagliflozin/3 tablets Metformin XR
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 50 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 7, 2017 · Synced Sep 23, 2026, 8:57 PM EDT
Recruiting Early Phase 1 Interventional

Pragmatic Trial of Metformin for Glucose Intolerance or Increased BMI in Prostate Cancer Patients

NCT05515978
View directory record Official record
Conditions
Prostate Cancer
Interventions
Metformin, Lifestyle Modification
Drug · Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2036
U.S. locations
4
States / cities
Aurora, Colorado • Colorado Springs, Colorado • Denver, Colorado + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Sep 23, 2026, 8:57 PM EDT
Recruiting Early Phase 1 Interventional

Relying on Pharmacotherapy to Improve Motor Gains in Chronic Stroke Survivors

NCT07588932
View directory record Official record
Conditions
Stroke
Interventions
Telmisartan, Metformin, Cilostazol
Drug
Lead sponsor
Spaulding Rehabilitation Hospital
Other
Eligibility
21 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Sep 23, 2026, 8:57 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Evaluation of Superiority of Valsartan+Celecoxib+Metformin Over Metformin Alone in Type 2 Diabetes Patients

NCT03686657
View directory record Official record
Conditions
Type 2 Diabetes, High Blood Pressure, Arthritis, Obesity
Interventions
Metformin, Val, Cel and Met XR Low, Val, Cel and Met XR High
Drug
Lead sponsor
ARKAY Therapeutics
Industry
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 23, 2026, 8:57 PM EDT
Completed Phase 2 Interventional Results available

A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin Therapy

NCT01649297
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo, empagliflozin (low dose qd), Empagliflozin (high dose qd), empagliflozin (high dose bid), empagliflozin (low dose bid)
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
983 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
39
States / cities
Florence, Alabama • Jonesboro, Arkansas • Lomita, California + 34 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2015 · Synced Sep 23, 2026, 8:57 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients

NCT01422876
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
high dose FDC, BI 10773 high dose, high dose FDC placebo, low dose FDC placebo, high dose BI 10773 placebo, low dose FDC, BI 10773 low dose, linagliptin, linagliptin placebo, BI 10773 low dose placebo, low dose BI 10773 placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
1,405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
112
States / cities
Birmingham, Alabama • Foley, Alabama • Mobile, Alabama + 90 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2015 · Synced Sep 23, 2026, 8:57 PM EDT
Completed Early Phase 1 Interventional

Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer

NCT01980823
View directory record Official record
Conditions
Breast Cancer, Breast Tumors, Cancer of Breast
Interventions
Metformin, Atorvastatin, Breast surgery
Drug · Procedure
Lead sponsor
Columbia University
Other
Eligibility
21 Years and older · Female only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 29, 2023 · Synced Sep 23, 2026, 8:57 PM EDT
Active, not recruiting Phase 2 Interventional

A Pilot Study of Ketogenic Diet and Metformin in Glioblastoma: Feasibility and Metabolic Imaging

NCT04691960
View directory record Official record
Conditions
Glioblastoma
Interventions
Ketogenic Diet, Metformin
Other · Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Sep 23, 2026, 8:57 PM EDT
Withdrawn Phase 4 Interventional

Ertugliflozin Versus Hydrochlorothiazide in Reducing Sympathetic Neural Overactivity in Patients With Hypertension and Recently-diagnosed Type 2 Diabetes.

NCT03640221
View directory record Official record
Conditions
Hypertension, Diabetes Mellitus, Type 2
Interventions
Ertugliflozin, Hydrochlorothiazide 12.5mg, Microneurography, SKNA recordings, Static Handgrip, Post-handgrip forearm vascular occlusion, Testing of the Arterial Baroreflex Function
Drug · Device · Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
35 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Sep 23, 2026, 8:57 PM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

Combination Gerotherapeutic Interventions for Healthspan Improvement

NCT07475546
View directory record Official record
Conditions
Healthspan Improvement, Aging, Longevity
Interventions
Rapamycin, Naltrexone, Metformin, NAD+, GSH, Infinite Supplement, Placebo/control, B12, Intervention: Guided Meditation Program, Control: Podcast Listening Activity, Control: Standard Exercise Regimen, Intervention: Structured Exercise Program
Drug · Dietary Supplement · Behavioral
Lead sponsor
AgelessRx
Industry
Eligibility
60 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 15, 2026 · Synced Sep 23, 2026, 8:57 PM EDT
Completed Phase 4 Interventional Results available

Metformin for Overweight & OBese ChILdren and Adolescents With BDS Treated With SGAs

NCT02515773
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Metformin, healthy lifestyle intervention (LIFE)
Drug · Behavioral
Lead sponsor
Melissa Delbello
Other
Eligibility
8 Years to 19 Years
Enrollment
1,565 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
29
States / cities
Covington, Kentucky • Neptune City, New Jersey • Amityville, New York + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2025 · Synced Sep 23, 2026, 8:57 PM EDT
Completed Phase 2 Interventional Results available

Empagliflozin (BI 10773) in Type Two Diabetes (T2D) Patients, Open Label Extension

NCT00881530
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
BI 10773, Metformin, Sitagliptin
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
660 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
12
States / cities
Mission Viejo, California • Spring Valley, California • Walnut Creek, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2014 · Synced Sep 23, 2026, 8:57 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer

NCT03424005
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Capecitabine, Atezolizumab, Ipatasertib, SGN-LIV1A, Bevacizumab, Chemotherapy (Gemcitabine + Carboplatin or Eribulin), Selicrelumab, Tocilizumab, Nab-Paclitaxel, Sacituzumab Govitecan, Abemaciclib, Fulvestrant, Ribociclib (Dose #1), Inavolisib (Dose #1), Trastuzumab Deruxtecan, Ribociclib (Dose #2), Letrozole, Inavolisib (Dose #2), Empagliflozin, Palbociclib, Metformin, Atirmociclib, Giredestrant
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
1,132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
24
States / cities
Duarte, California • Irvine, California • La Jolla, California + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Sep 23, 2026, 8:57 PM EDT
Completed Phase 4 Interventional Results available

Intervention to Promote Weight Loss in Latinas At-risk for Diabetes

NCT02088034
View directory record Official record
Conditions
Diabetes
Interventions
Promotora-led Intervention, Metformin Therapy, Usual Care
Behavioral · Drug · Other
Lead sponsor
Temple University
Other
Eligibility
20 Years to 75 Years · Female only
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 21, 2020 · Synced Sep 23, 2026, 8:57 PM EDT